Table 4

Ca2+-handling proteins

ShamPMIBNP-PMIBB-PMIBB-BNP-PMI
SERCA2a (/GAPDH)0.51±0.120.25±0.05*0.24±0.09*0.70±0.05*,||0.84±0.04†,||
NCX1 (/GAPDH)0.38±0.020.67±0.02†0.61±0.02†0.52±0.02*,§0.43±0.04||,¶
S100A1 (/GAPDH)0.85±0.070.59±0.06†0.49±0.03‡0.72±.041||0.69±0.03||
PSer16-PLB (/GAPDH)1.00±0.030.54±0.01*0.70±0.01*1.53±0.02†,§,#0.83±0.02
PLB (/GAPDH)2.01±0.032.51±0.02*2.42±0.02*2.12±0.04§1.64±0.02*,||,#
PSer16-PLB to PLB ratio0.49±0.010.17±0.02†0.20±0.01†0.72±0.01†,§0.53±0.03||,#
Pser2808-RyR (/GAPDH)0.53±0.040.47±0.060.57±0.090.48±0.050.24±0.04
RyR (/GAPDH)0.48±0.040.35±0.05*0.61±0.09§0.62±0.05*,§0.48±0.03*,§,#
Pser2808-RyR to RyR ratio1.12±0.091.51±0.10*1.20±0.080.73±0.03*,||0.43±0.07†,¶,#
  • BB+BNP normalised expression and post-traductional modifications of Ca2+-handling proteins. Normalised protein content to GAPDH for SERCA2a, NCX1, S100A1, PSer16-PLB, PLB, PSer2808-RyR and RyR. The ratio of PSer16-PLB to PLB and PSer2808-RyR to RyR were calculated. *,†,‡ p<0.05, p<0.01, p<0.001 versus Sham; §,||,¶ p<0.05, p<0.01, p<0.001 versus PMI animals; # p<0.05 versus BB-PMI animals (n=10/group).

  • BB, β1-adrenergic blocker; BNP, B-type natriuretic peptide; PMI, postmyocardial infarction.